According to BSE under 5000 crore market capitalisation, makes companies eligible for small-cap companies. These companies are placed from 251 positions onwards in BSE list. Small stocks made a mark in 2020 after delivering negative returns in the last two years. As Covid set in and supplies from China froze, big-cap companies experienced a selling spree the from investors. Increased retail investor participation in pandemic times saw small-cap index surging up to 31 per cent and outperform big-cap companies.
Here we present you with the Top Ten mid-cap pharma companies
Ever since inception in 2002 SeQuent has emerged as an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation).The company have branded our Animal Health business as Alvira Animal Health with a singular focus to create value in the global animal health space. We cater to unaddressed global market requirements and focus on products for livestock, poultry and companion animals. Our value proposition includes laboratory and technical support services.80 countries 500 formulations 12 dosage form. CEO - Manish Gupta
Solara Active Pharma Sciences
Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer-oriented API manufacturer. The company have a legacy of over three decades and trace their origins to the API expertise of Strides Shasun Ltd. and the technical know-how of human API business from Sequent Scientific Ltd. Company bridges the industry gap by delivering value-based products while maintaining focus on customer needs. Solarahave 140+ scientists working at two R&D Centers and 5 API manufacturing facilities armed with global approvals and 2 dedicated R&D facilities. Manufacturing Facilities are situated in Ambernath, Mangaluru, Pondicherry, Cuddalore while Chennai Bangalore houses research facilities. CEO- Bharath R Sesha
The company which was established in 1986, is India's one of the leading generic pharmaceutical company and is a significant player in the Organic chemicals space. IOLCP has a wide presence across various therapeutic categories like Pain Management, Anti-diabetic, Antihypertensive, Anti Convulsants, etc.. Company capabilities are nurtured by pursuing & implementing the high standards of excellence in our operations. Products cater to the key industrial sectors of Pharmaceutical, Flexible Packaging, Paint & Lamination, Ink, Pesticides, etc. Efficient teamwork & strong associations have guided us to success. Accolades for our environmental policies have come from the highest levels of power.IOLCP, a leading manufacturer of Active Pharma Ingredients and Specialty chemicals operates its manufacturing facilities from Barnala (Punjab). The state of the art facilities as per current GMP guidelines spread over 56 Acres of land at a single location. Key pharmaceutical intermediates and speciality chemical plants are DCS controlled continuous process plants. All plants are designed as per the latest technology and ISO standards. Quality Operations include a stand-alone facility for Quality Assurance, Quality Control & Microbiology Labs.CEO - Varinder Gupta
A speciality chemical manufacturing company in India, backed by a legacy of 35 years, have established a reputation of being a highly reliable supplier and a diversified product player, one that is capable of not only meeting but also anticipating market needs. Valiant Organics Limited is a chemical manufacturing company with its focus on manufacturing and marketing of speciality chemicals. The products find several applications mainly in the agrochemical, pharmaceutical, rubber, dyes, pigment and in the making of veterinary drugs. Company has integrated manufacturing facilities at Sarigam, Tarapur, Vapi, Jhagadia, and Ahmedabad manufacture diversified products and offer maximum capacity utilisation. The business was originally set up in 1984 as a partnership concern under the name of Valiant Chemical Corporation. It was later incorporated as a private limited company in 2005 with the aim of acquiring this partnership firm and, subsequently, the business has been run in our Company. In 2015, the Company was further converted into public limited company. Currently, company exports to Asia, Europe, and the USA, and are scouting for more international destinations to supply their products. Port cities of Tarapur, Sarigam, Vapi, Jhagadia, Ahmedabad has manufacturing facilities while it's headquartered in Mumbai. CEO - Arvind K Chedda
Caplin Point Laboratories
Caplin Point Laboratories is one of the fastest-growing mid-cap pharmaceutical companies in India. The company holds over 2800 product licenses across the globe, with a dominant position in Latin America. Topline of the company in 2010 has become the bottom line in 2016 with Debt-free business model and supported by benchmark receivables. Company is entering into Regulated markets of US, EU, Brazil, Mexico, Australia, with a state of the art manufacturing facility for Injectables, already approved by EU-GMP, ANVISA and US FDA. Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last-mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies. Caplin Point has over 2000 products licenses across the globe with a further 300 in the pipeline for emerging markets. CEO - Sridhar Ganesan
Advanced Enzymes is a research-driven company with global leadership in manufacturing of enzymes and probiotics. Advanced Enzyme is the largest Indian enzyme company engaged in the research and development, manufacturing and marketing of 400+ proprietary products developed from over 65 indigenous enzymes & probiotics. The objective is to help consumers access side-effect-free healthcare, help farmers enhance nutrition for animals, and also to help the industry replace traditional thermal-chemical-mechanical processes into enzyme passed processes. Having pioneered the production of enzymes in India, the company continues to set trends with the research & development of new applications for the use of enzymes across various industries. Equipped with state-of-the-art manufacturing facilities and research & development centres across India, U.S. and Europe. Today, Advanced Enzymes with three wholly-owned subsidiaries, three joint ventures and five step-down subsidiaries is able to service 700 customers across 45 countries worldwide. With exports across 6 continents, the company provides customized and effective enzyme solutions coupled with the best in technical advice and superior service. CEO - C. L. Rathi
Shilpa Medicare has been on the path of expansion ever since its inception in 1987. With a regulatory recognized manufacturing set up and excellent scientific expert team in place, Shilpa Medicare has since been on a steady growth path. Currently, one of the leaders in the Oncology market who offers a complete range of products in this segment spanning across APIs, formulations both in terms of R&D and manufacturing capabilities. Further to consolidation in the field of oncology API and formulations, we are striving to put in our efforts in the field of novel drug delivery systems and biotech products along with widening our focus to other therapy areas. Where we are today has been the result of our constant endeavours for more than two decades. Shilpa Medicare Limited is one of the largest speciality generic pharmaceutical companies in the world. With a presence in 100 countries worldwide and 6 manufacturing facilities. CEO - Vishnukant Chaturbhuj Bhutada
Started on 23rd August 1947, Indoco Remedies Ltd., is a fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a USD 145 million company, employs around 6000 personnel, including over 300 skilled scientists. The company have 9 manufacturing facilities, out of which, 6 are for finished dosages and 3 for APIs, supported by a state-of-the-art R&D centre at Rabale, Navi Mumbai and a Clinical Research Organisation at Hyderabad. Our manufacturing facilities are of highest regulatory standards, complying with WHO-cGMP guidelines and have been approved by various regulatory authorities such as USFDA, UK-MHRA, SUKL-Czech Republic, Cofepris – Mexico, TGA-Australia, JAZMP- Slovenia, MCC-South Africa, NDA-Uganda, TFDA-Tanzania, SBD-Yemen, MOH-Ukraine, PPB-Kenya and FDA-Ghana. Indoco has strengthened its wings in the international markets and offers complete solutions, including product development, manufacture and supply of Finished Dosages, APIs and Intermediates to generic companies worldwide. We have a large basket of products backed by ANDAs / eCTD Dossiers and Drug Master Files (DMFs).Expertise in Research & Development, backward integration in API in select products, own CRO set-up, excellence in Finished Dosages manufacturing and a strong customer base will ensure consistent growth in the Company’s Domestic, as well as international business. CEO - Aditi Panandikar
Unichem Laboratories was founded in 1944 by Padmabhushan Late Mr Amrut V Mody, a pioneer in the Indian pharmaceuticals business. The initial public offering of Unichem Laboratories Limited was in 1963, and the company was consequently listed on BSE Limited and NSE Limited. It is one of India's oldest and largest pharmaceutical companies, headquartered in Mumbai, Maharashtra, India. Unichem is an international, business-oriented, integrated, speciality pharmaceutical company known for its quality and reliability. It manufactures and markets a large basket of pharmaceutical formulations across the globe, including the regulated markets of the US and Europe. Unichem Laboratories Limited is currently active in finished formulations, APIs, contract manufacturing, custom synthesis etc. Their R & D site at Goa has expertise in product development, process chemistry and developing complex APIs for the global market. Unichem's Formulations manufacturing facilities are located at Goa, Ghaziabad (Uttar Pradesh) and Baddi (Himachal Pradesh). Active Pharmaceutical Ingredient (API) manufacturing facilities are located at Roha (Maharashtra), Pithampur (Madhya Pradesh) and Kolhapur (Maharashtra). Out of the 6 Manufacturing Sites, 4 are USFDA approved and have approvals from other major health authorities. The Company's facilities have been approved by various international health authorities such as USFDA, UK MHRA, ANVISA (Brazil), COFEPRIS (Mexico), PMDA (Japan), TGA (Australia), SAPHRA (South Africa) and MFDS(Korea), EDQM (European Directorate for the Quality of Medicines), TPD (Canada). CEO - Prakash A Mody
Watch this space as we bring you the hottest stocks of every segment With inputs from Snehangshu Dasgupta.